However, the disappointing clinical trial outcomes with beta-secretase 1 (BACE-1) inhibitors (e.g., aducanumab and verubecestat) indicate that BACE-1 inhibition alone could not successfully treat AD, although this property offer benefits in the management of AD [31,32]. The gene discussed is BACE1; the disease is Alzheimer disease.